Cyclopharm (ASX:CYC) LT-Debt-to-Total-Asset : 0.09 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cyclopharm's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.09.

Cyclopharm's long-term debt to total assets ratio increased from Dec. 2022 (0.08) to Dec. 2023 (0.09). It may suggest that Cyclopharm is progressively becoming more dependent on debt to grow their business.

Cyclopharm LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cyclopharm's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm LT-Debt-to-Total-Asset Chart

Cyclopharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.15

0.16

0.08

0.09

Cyclopharm Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.08	0.08	0.08	0.08	0.09

Cyclopharm LT-Debt-to-Total-Asset Calculation

Cyclopharm's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	4.013	/	45.914
	=	0.09

Cyclopharm's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	4.013	/	45.914
	=	0.09

Cyclopharm (ASX:CYC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cyclopharm LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cyclopharm's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclopharm (ASX:CYC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cyclopharm Ltd (ASX:CYC) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208

Website

https://cyclopharm.com.au

Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm (ASX:CYC) Headlines

No Headlines